Skip to main content

Table 1 Clinical characteristics of the AIDS-PCP patients between survivors and non-survivors

From: Activation of the kynurenine pathway is associated with poor outcome in Pneumocystis pneumonia patients infected with HIV: results of 2 months cohort study

 

Survivors

(n = 38)

Non-survivors

(n = 11)

P-value

Sex, M/F

37/1

11/0

NA

Age, yr

40.97 ± 14.29

43.55 ± 16.48

0.684

Body mass index

19.69 ± 2.648

20.90 ± 2.43

0.274

CD4+ cell count, cells/mm3(ul)

59.28 ± 30.38

47.15 ± 28.71

0.387

D-dimer

1314.34 ± 1697.91

5427.91 ± 8050.52

0.010

Albumin

33.05 ± 5.26

25.37 ± 5.99

0.001

CRP

39.88 ± 148.75

91.74 ± 56.27

0.007

ESR

60.23 ± 25.96

66.00 ± 30.17

0.615

P/F ratio, mmHg

398.34 ± 135.17

318.33 ± 106.62

0.144

LDH

339.55 ± 148.75

543.38 ± 328.44

0.045

Kynurenine

2.93 ± 2.19

4.32 ± 3.56

0.051

Tryptophan

15.48 ± 3.13

15.54 ± 3.66

0.952

Kyn/Trp (mM/M)

169.05 ± 72.40

275.91 ± 132.03

0.002

PaO2/FiO2 ≤ 300 mmHg, No. (%)

9 (9/38)

9 (9/11)

0.001

Patients receiving ART, No. (%)

6 (6/38)

4 (4/11)

0.201

Treatment for PCP

38

11

NA

  1. Data are expressed as mean and SD